


**Product Name** : TG-101209  
**Cat. No.** : PC-42570  
**CAS No.** : 936091-14-4  
**Molecular Formula** : C<sub>26</sub>H<sub>35</sub>N<sub>7</sub>O<sub>2</sub>S  
**Molecular Weight** : 509.6668  
**Target** : JAK  
**Solubility** : 10 mM in DMSO  
4. Wang Y, et al. Blood. 2009 Dec 3;114(24):5024-33.



## Biological Activity

A potent, selective, orally bioavailable JAK2 inhibitor with IC<sub>50</sub> of 6 nM; also inhibits FLT3 (IC<sub>50</sub>=25 nM) and RET (IC<sub>50</sub>=17 nM) kinases, weakly inhibits JAK3 (IC<sub>50</sub>=168 nM); inhibits growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with IC<sub>50</sub> of 200 nM, induces cell cycle arrest and apoptosis, and inhibits phosphorylation of JAK2V617F, STAT5 and STAT3; attenuates myelofibrosis in murine model of JAK2V617F-induced polycythemia vera; also potently inhibits BRD4 with K<sub>d</sub> of 123 nM.

Bone Cancer

Preclinical

## References

Pardanani A, et al. Leukemia. 2007 Aug;21(8):1658-68.

Libani IV, et al. Blood. 2008 Aug 1;112(3):875-85.

Ciceri P, et al. Nat Chem Biol. 2014 Apr;10(4):305-12.

